Halozyme Announces Multiple Commercial Supply Agreements for the Manufacture of rHuPH20
SAN DIEGO, April 5, 2010 /PRNewswire via COMTEX/ --Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced the execution of multiple commercial supply agreements with its existing manufacturing partners. Halozyme amended an existing commercial supply agreement with Avid Bioservices, Inc., entered into a new commercial supply agreement with Avid and entered into a new commercial supply agreement with Cook Pharmica LLC. These three agreements are expected to cover the commercial production of recombinant human hyaluronidase (rHuPH20) to be used in the manufacture of both current products as well as certain partnered product candidates such as subcutaneous Herceptin(R) and GAMMAGARD(R) with rHuPH20. Subcutaneous Herceptin and GAMMAGARD with rHuPH20 are both currently in Phase 3 clinical trials.
"We are pleased to strengthen our already robust supply chain for rHuPH20 by securing these commercial supply agreements to support existing products as well as exciting partnered product candidates such as subcutaneous Herceptin and GAMMAGARD with rHuPH20," stated Jonathan E. Lim, M.D., Halozyme's president and CEO.
Specific financial terms of these commercial supply agreements have not been disclosed.
Halozyme Re-focusing Efforts (in prep. for partnership/buyout??) – I can’t tell on initial read if any impact on their Avid expenditures going forward...
RECALL, THE 4-5-10 ANNOUNCED AVID/HALOZYME EXTENSION/EXPANSION AGREEMENT SAID THIS: 4-5-10: “Avid Bioservices and Halozyme Therapeutics Expand Commercial Supply Relationship With New Manufacturing Agreements - Avid Designated a Preferred Supplier for Halozyme” See: http://tinyurl.com/yfdgsom TUSTIN, April 5 2010: Avid Bioservices, Inc., a wholly-owned subsidiary of Peregrine Pharmaceuticals, Inc. (PPHM), today announced that it has expanded its commercial supply relationship with Halozyme Therapeutics, Inc. with new manufacturing agreements. The companies have also entered into a long-term strategic relationship with Halozyme designating Avid a preferred supplier for future products requiring Avid's process development and biomanufacturing capabilities and expertise. Avid has manufactured commercial product for Halozyme since 2005 in the company's current cGMP facility. As part of the new agreements, the companies have amended and extended their existing commercial supply agreement for recombinant human hyaluronidase ("rHuPH20"), used in 2 of Halozyme's marketed products. In addition, the companies have signed a new commercial supply agreement for additional rHuPH20 products. Specific financial terms of these commercial supply agreements have not been disclosed. "We are pleased to strengthen our already robust supply chain for rHuPH20 with these new agreements with Avid, supporting our existing products as well as partnered product candidates," said Jonathan E. Lim, M.D., Halozyme's president and CEO. "Expanding our commercial supply relationship with Avid is a testament to the strong relationship we have developed over the past 5 years.""We are delighted to extend the Hylenex & Cumulase supply agreement, and expand our long-term relationship with Halozyme as we partner with them to support their current & future commercial and clinical process dev. and biomanufacturing needs," said Christopher E. Eso, Avid's VP, business operations. "Our solid client relationships and dedicated team at Avid have been critical to ensuring our clients' success."
= = = = = = = = = = = = = = = AVID BIOSERVICES, Inc. (Peregrine's Mfg. Subsidiary): http://www.avidbio.com • 4-5-10: Avid & Halozyme Expand Commercial Supply Relationship: http://tinyurl.com/yfdgsom …”the companies extended their existing commercial supply agreement (CSA) for rHuPH20 and signed a new CSA for addl. partnered product candidates such as subcutaneous HERCEPTIN & GAMMAGARD with rHuPH20.” • 8-6-10: Avid & Cook remain Halozyme's 2 CMO's: http://tinyurl.com/2a89bvj
News 
Market Data 
Discover 
